Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, 18-70 years of age
Patients with either unresectable Stage IIIc or IV BRAFV600 mutation-positive metastatic melanoma or other malignant BRAFV600 mutation-positive tumor type and who have no acceptable standard treatment options
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
Full recovery from any major surgery or significant traumatic injury at least 14 days prior to the first dose of study treatment
Adequate hematologic and end organ function
Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to use 2 effective methods of contraception as defined by protocol during the course of the study and for at least 6 months after completion of study treatment
You may not be if
Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of Day 1
Prior anti-cancer therapy within 28 days (6 weeks for nitrosureas or mitocyn C, or 14 days for hormonal therapy or kinase inhibitors) before the first dose of study treatment Day 1
Palliative radiotherapy within 2 weeks prior to first dose of study treatment Day 1
Experimental therapy within 4 weeks prior to first dose of study treatment Day 1
History of clinically significant cardiac or pulmonary dysfunction, including current uncontrolled Grade \>/=2 hypertension or unstable angina
Current Grade \>/=2 dyspnea or hypoxia or need for oxygen supplementation
History of myocardial infarction within 6 months prior to first dose of study treatment
Active central nervous system lesions (i.e. participants with radiographically unstable, symptomatic lesions)
History of bleeding or coagulation disorders
Allergy or hypersensitivity to vemurafenib or acenocoumarol formulations
History of malabsorption or other condition that would interfere with the enteral absorption of study treatment
Participants with VKORC1 mutations (1639G\→A, 1173C\→T) in either one allele (heterozygous)or two alleles (homozygous)
Participants with CYP2C9\*3 mutations in either one allele (heterozygous) or two alleles (homozygous)
History of clinically significant liver disease (including cirrhosis), current alcohol abuse, or active hepatitis B or hepatitis C virus infection
Human immunodeficiency virus (HIV) infection requiring antiretroviral treatment, or AIDS-related illness
Pregnant or lactating women
Clareo Health | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
